drugset / Trial / NCT03035890
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
Completed
35 enrolled
West Virginia University
West Virginia Clinical and Translational Science Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer to immunotherapy and to monitor any side effects.
Timeline
- Start
- 2017-01-23
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 2 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |